Phase 3 Chronic kidney disease trials recruiting now

All Chronic kidney disease trials, every phase

Other phases for Chronic kidney disease

Phase 3 Chronic kidney disease trials

• A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients
  NCT06578078 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 6 locations
• A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
  NCT06466785 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
  NCT03969329 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 23 locations
• A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease
  NCT07419828 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 771 locations
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 186 locations
• A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
  NCT07223502 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia
  NCT07494409 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
  NCT07487727 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
  NCT07241390 · Phase: Phase 3 · Ages: 50 Years and older · Sex: All (male and female) · 566 locations
• A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
  NCT05970172 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 47 locations
• A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
  NCT06933472 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 42 locations
• A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
  NCT03619850 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 21 locations
• A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
  NCT07107945 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · 93 locations
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 715 locations
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female) · 151 locations
• A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
  NCT03633708 · Phase: Phase 3 · Ages: 0 Years to 18 Years · Sex: All (male and female) · 43 locations
• Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction
  NCT05562869 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
  NCT06337838 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
  NCT05931276 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Chronic Anticoagulation With a Reduced Dose Regimen of Rivaroxaban in End-stage Renal Disease Patients
  NCT05410275 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease
  NCT05422534 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Colchicine in Chronic Kidney Disease Patients
  NCT06998862 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1114 locations
• Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)
  NCT03627013 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Dapagliflozin for Cardio-renal Protection After ICU Discharge
  NCT07025629 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 557 locations
• Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
  NCT05726916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Effect of Ketosteril on Sarcopenia in Patients With Chronic Kidney Disease
  NCT06329622 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
  NCT06982079 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
  NCT03994471 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
  NCT05510323 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
  NCT03321656 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease
  NCT05732727 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 40 locations
• Keeping RAASi Treatment With Optimal Potassium Control
  NCT06578533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Ketoanalogue Supplementation for Muscle Protection in CKD 4 and 5 Patients With Moderately Low Protein Diet (KETO-PROT-ACTION)
  NCT07374042 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location
• Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
  NCT06858319 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · 26 locations
• Patient-driven Management of BP in CKD
  NCT05546099 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Patiromer and Diet/hrQoL in Chronic Dialysis
  NCT06858280 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Phase 3 Clinical Trial with Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
  NCT05944016 · Phase: Phase 3 · Ages: 10 Years to 39 Years · Sex: All (male and female) · 16 locations
• SAfety of Regional Citrate Anticoagulation (SARCA Study)
  NCT05339139 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF
  NCT05852704 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Shingrix in Renal Transplant Recipients
  NCT04128189 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 4 locations
• Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
  NCT06217302 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 19 locations
• Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation
  NCT05679024 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
  NCT07122401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
  NCT07119372 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
  NCT07498335 · Phase: Phase 3 · Ages: 2 Years to 18 Years · Sex: All (male and female) · 9 locations
• The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
  NCT06058585 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
  NCT05715814 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.